Treatment of AIDS-related Kaposi's sarcoma with recombinant gamma-interferon.
Four patients with the acquired immunodeficiency syndrome and Kaposi's sarcoma were treated with subcutaneous human recombinant gamma-interferon at a dosage of 200 micrograms = 2 X 10(6) U twice daily for at least 28 days. While the dosage of interferon was well tolerated, progressive disease was observed in all four patients studied. These results might be due to the selection of the patients presenting advanced stages (3 out of 4) with recurrent disease after previous chemotherapy.
D000163:Acquired Immunodeficiency Syndrome / Q000628:therapy*; D000328:Adult; D017977:Deltaretrovirus; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012192:Retroviridae Infections / Q000628:therapy*; D012514:Sarcoma, Kaposi / Q000628:therapy*; D012878:Skin Neoplasms / Q000628:therapy*
D011994:Recombinant Proteins; D007371:Interferon-gamma